ATE242765T1 - S-2'-(2-(1-methyl-2-piperidyl) ethyl) cinnamanilide als 5-ht2 rezeptor antagonist - Google Patents

S-2'-(2-(1-methyl-2-piperidyl) ethyl) cinnamanilide als 5-ht2 rezeptor antagonist

Info

Publication number
ATE242765T1
ATE242765T1 AT98903668T AT98903668T ATE242765T1 AT E242765 T1 ATE242765 T1 AT E242765T1 AT 98903668 T AT98903668 T AT 98903668T AT 98903668 T AT98903668 T AT 98903668T AT E242765 T1 ATE242765 T1 AT E242765T1
Authority
AT
Austria
Prior art keywords
mpec
cinnamanilide
piperidyl
ethyl
methyl
Prior art date
Application number
AT98903668T
Other languages
English (en)
Inventor
M Samir Amer
Original Assignee
M Samir Amer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25204013&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE242765(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by M Samir Amer filed Critical M Samir Amer
Application granted granted Critical
Publication of ATE242765T1 publication Critical patent/ATE242765T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT98903668T 1997-02-28 1998-01-23 S-2'-(2-(1-methyl-2-piperidyl) ethyl) cinnamanilide als 5-ht2 rezeptor antagonist ATE242765T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/810,503 US5780487A (en) 1995-08-07 1997-02-28 S-2'- 2-(1-methyl-2-piperidyl) ethyl! cinnamanilide
PCT/US1998/001304 WO1998038165A1 (en) 1997-02-28 1998-01-23 S-2'-(2-(1-methyl-2-piperidyl) ethyl) cinnamanilide as a 5-ht2 receptor antagonist

Publications (1)

Publication Number Publication Date
ATE242765T1 true ATE242765T1 (de) 2003-06-15

Family

ID=25204013

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98903668T ATE242765T1 (de) 1997-02-28 1998-01-23 S-2'-(2-(1-methyl-2-piperidyl) ethyl) cinnamanilide als 5-ht2 rezeptor antagonist

Country Status (11)

Country Link
US (1) US5780487A (de)
EP (1) EP0973741B1 (de)
JP (1) JP3492378B2 (de)
KR (1) KR20000075696A (de)
AT (1) ATE242765T1 (de)
AU (1) AU750603B2 (de)
CA (1) CA2282840C (de)
DE (1) DE69815518T2 (de)
ES (1) ES2201440T3 (de)
NO (1) NO318443B1 (de)
WO (1) WO1998038165A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10036802A1 (de) * 2000-07-28 2002-02-07 Tesa Ag Haftklebemassen auf Basis von Blockcopolymeren der Struktur P(A)-P(B)-P(A)
AU2002364549B2 (en) * 2001-12-10 2007-11-22 Amgen, Inc Vanilloid receptor ligands and their use in treatments
US7600626B2 (en) * 2002-06-13 2009-10-13 Cummins-Allison Corp. Currency processing and strapping systems and methods
DE10358525A1 (de) 2003-12-13 2005-07-07 Bayer Healthcare Ag Endoparasitizide Mittel zur topischen Applikation
AU2006340837A1 (en) * 2005-11-17 2007-10-04 Novartis Ag Organic compounds
US20080300410A1 (en) * 2005-11-17 2008-12-04 Mahavir Prashad Organic Compounds
EP2346511A2 (de) * 2008-10-22 2011-07-27 Sam Amer&Co., Inc. Verfahren zur behandlung von lungenarterien-hypertonie
WO2012026914A1 (en) * 2010-08-23 2012-03-01 Sam Amer & Co., Inc. Methods and compositions for treating internal and external hemorrhoids
WO2013070236A1 (en) * 2011-11-11 2013-05-16 Ventrus Biosciences, Inc. Methods and compositions for treating hemorrhoids while providing local anesthetic and anti-inflammatory effects
CN102924374B (zh) * 2012-02-15 2014-04-16 湖北欣瑞康医药科技有限公司 喹啉-4-羧酸衍生物的制备方法
CH706161A1 (de) 2012-03-15 2013-10-15 Oti Greentech Group Ag Ölrückgewinnung.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000143A (en) * 1971-03-03 1976-12-28 Mead Johnson & Company Substituted piperidines
US4064254A (en) 1971-03-03 1977-12-20 Mead Johnson & Company Substituted piperidines therapeutic process and compositions
US5266571A (en) * 1992-01-09 1993-11-30 Amer Moh Samir Treatment of hemorrhoids with 5-HT2 antagonists
GB9402688D0 (en) * 1994-02-11 1994-04-06 Merck Sharp & Dohme Therapeutic agents

Also Published As

Publication number Publication date
NO318443B1 (no) 2005-03-21
WO1998038165A1 (en) 1998-09-03
AU6037798A (en) 1998-09-18
JP2001527521A (ja) 2001-12-25
NO994181L (no) 1999-10-27
CA2282840A1 (en) 1998-09-03
US5780487A (en) 1998-07-14
CA2282840C (en) 2006-04-11
JP3492378B2 (ja) 2004-02-03
ES2201440T3 (es) 2004-03-16
EP0973741A1 (de) 2000-01-26
KR20000075696A (ko) 2000-12-26
EP0973741B1 (de) 2003-06-11
NO994181D0 (no) 1999-08-27
AU750603B2 (en) 2002-07-25
DE69815518D1 (en) 2003-07-17
DE69815518T2 (de) 2004-04-22

Similar Documents

Publication Publication Date Title
ATE242765T1 (de) S-2'-(2-(1-methyl-2-piperidyl) ethyl) cinnamanilide als 5-ht2 rezeptor antagonist
DK0735868T3 (da) Anvendelse af ikke-steroide cyclooxygenaseinhibitorer til fremstilling af et medikament til behandling af forhøjet intrakul
ATE374749T1 (de) Indol-derivate als antientzündungs wirkstoffe
GEP20033131B (en) Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity
NO20071490L (no) Farmasoytisk aktive isoindolderivater
SE9503924D0 (sv) Novel opioid peptides
MX9307779A (es) Compuestos benzoicos fundidos.
ES2089665T3 (es) Terazosina polimorfa y composicion farmaceutica.
KR910018020A (ko) 프라바스타틴과 피브르산 유도체의 혼합제. 및 이 혼합제를 사용한 이상지혈증 치료 방법
ES2102994T3 (es) Derivados de benzisotiazolinona-1-dioxido como inhibidores de elastasa.
IL111127A (en) Short-acting calcium antagonist dihydropyridines process for their preparation and pharmaceutical compositions containing them
BR0013935A (pt) IsÈmeros oticamente ativos de cetotifeno e metabólitos terapeuticamente ativos dos mesmos
IT1250049B (it) Composti triciclici.
MY111055A (en) Pharmaceutical composition and process for the preparation thereof
TR200200263T2 (tr) Yeni seçiçi retinoid agonistleri
CO5200778A1 (es) Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de b enzimidazol, administrada para prevenir y tratar el cancer e inhibir la metastasis
GEP20012389B (en) Benzoxazinone Dopamine D4 Receptor Antagonists, Pharmaceutical Composition Containing the Same and Method for Treatment of Psychosis or Schizophrenia
ES2106531T3 (es) Compuestos de dibenzoxazepina substituidos en 2, 3, 4, 5, 6, 7, 8, 9 y/o 10, composiciones farmaceuticas y metodos de uso.
EA199800013A1 (ru) Способы минимизации остеопороза
KR960700696A (ko) 정맥성 질환 치료에 유용한 5-하이드록시트립타민-2 수용체 길항물질 조성물(5-ht₂receptor antagonist compositions useful in treating venous conditions)
AU3623399A (en) Use of benzofuroxan derivatives in treating angina pectoris
KR950003262A (ko) 1- 아릴옥시-3- 알킬아미노-2-프로판올 니트레이트 에스테르, 이의 용도 및 상응하는 약제학적 조성물
ES2093246T3 (es) Compuestos de benzazepina terapeuticos.
FI950209A0 (fi) Farmakologisesti aktiiviset alfa-(tertiaarinen-amino-metyyli)-bentseenimetanolijohdannaiset
ECSP941088A (es) Composiciones

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties